Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Aptose Biosciences ( (TSE:APS) ) has provided an announcement.
On February 18, 2025, Aptose Biosciences announced a Reverse Share Split, consolidating its outstanding common shares on a 1-for-30 basis. This move aims to restore compliance with Nasdaq’s minimum bid price requirement and ensure continued access to diverse investors. The Reverse Share Split is subject to regulatory approvals and is expected to take effect on February 26, 2025, impacting the company’s stock trading on both the TSX and Nasdaq.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, with an emphasis on hematology. The company is advancing a pipeline of small molecule cancer therapeutics, including its lead oral kinase inhibitor, tuspetinib, which is being developed for use in acute myeloid leukemia (AML).
YTD Price Performance: -23.40%
Average Trading Volume: 9,503,832
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $10.81M
For a thorough assessment of APS stock, go to TipRanks’ Stock Analysis page.
